Global Diabetes Devices and Drugs Market: SGLT-2 Inhibitors Segment to Expand at Impressive 76.80% CAGR from 2013 to 2019
The global diabetes devices and drugs market will expand at a moderate CAGR of 5.90% during the forecast period from 2013 to 2019, according to a report from Transparency Market Research (TMR). This report is titled “Diabetes Devices and Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019”. In 2012, the global diabetes devices and drugs market was worth more than US$54.0 bn and by 2019, the market is projected to be worth US$83.0 bn.
Therapy-wise, the global diabetes devices and drugs market is segmented into insulin, non-insulin injectable anti-diabetes drugs, and oral anti-diabetes drugs. Long-acting insulin derivatives held a share of 42.7% in the global diabetes devices and drugs market in 2012. Among oral anti-diabetes drugs, the SGLT-2 inhibitors segment will witness a remarkable CAGR of 76.80% during the forecast period.
Report overview @ https://www.transparencymarketresearch.com/diabetes-devices-market.html
The global diabetes devices and drugs market is segmented into two segments, namely; diabetes devices and diabetes drugs class. Diabetes devices segment is divided into diabetes diagnostic and monitoring devices and insulin delivery devices. Diabetes diagnostic and monitoring devices class is further split into analog glucose meters, test strips, lancets and lancing devices, CGM devices and others. Insulin delivery devices class is divided into insulin pens, insulin syringes, insulin pumps and insulin injectors. The second segment of the market, that is, drugs class is fragmented into insulin derivatives, oral anti-diabetes drugs (OADs) and non insulin injectable anti-diabetes drugs. Insulin derivatives are categorized on the basis of their time of action, such as, rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Oral anti-diabetes drugs are divided into sulphonylureas, biguanides, meglitinides, alpha glucosidase inhibitors, thiazolidinediones, DPP-IV inhibitors, and SGLT2 inhibitors. GLP-1 agonists represent the injectable anti-diabetes drugs class. The report also provides in-depth analysis of pipeline diabetes drugs.
Request A Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14
Summary of Table of Content
Introduction
Executive Summary
Disease Overview: Diabetes
Market Overview
Diabetes Devices Market, by Device Types
Global Diabetes Drugs Market, by Drug Therapy
Diabetes Devices and Drugs Market Revenue, by Geography
Competitive Landscape
Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=14<ype=S
About Us
Transparency Market Research (TMR) is a global
market intelligence company providing business information reports
and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight for
thousands of decision makers. TMR’s experienced team of analysts,
researchers, and consultants use proprietary data sources and various
tools and techniques to gather and analyze information.
TMR’s
data repository is continuously updated and revised by a team of
research experts so that it always reflects the latest trends and
information. With extensive research and analysis capabilities,
Transparency Market Research employs rigorous primary and secondary
research techniques to develop distinctive data sets and research
material for business reports.
Contact
Transparency
Market Research
State Tower,
90 State Street,
Suite
700,
Albany NY - 12207
United States
Tel:
+1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Sales:
sales@transparencymarketresearch.com
Website:
www.transparencymarketresearch.com
Blog: http://www.tmrblog.com/
